Clinical Trials Logo

Clinical Trial Summary

This is a prospective multi-center, open-label, single arm, Phase II study to investigate the safety and efficacy of BKM120 in patients with advanced endometrial carcinoma whose disease progressed on or after a first-line antineoplastic treatment. Patients will receive BKM120 orally at a dose of 100 mg/day. Availability of tumor specimen (either archival tissue or a fixed fresh biopsy) is mandatory for assessment of the PI3K (Phosphatidylinositol 3 Kinase (PI3K) pathway activation status.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT01289041
Study type Interventional
Source Novartis
Contact
Status Completed
Phase Phase 2
Start date February 2011
Completion date March 2014

See also
  Status Clinical Trial Phase
Recruiting NCT04574284 - A Study of TQB2450 Injection Combined With Anlotinib Hydrochloride Capsule in Subjects With Advanced Endometrial Cancer Phase 2
Withdrawn NCT06046274 - GEN1046 in Combination With Anticancer Agents for the Treatment of Advanced Endometrial Cancer Phase 2
Recruiting NCT05112991 - Study of Envafolimab Alone or With Lenvatinib in Patients With Advanced Endometrial Cancer Phase 2
Not yet recruiting NCT05106127 - Safety Lead-In Study of a Repurposed Drug Added to the Combination of Len Plus Pem Phase 2
Not yet recruiting NCT05077215 - Efficacy and Safety of a Repurposed Drug Added to the Combination of Len Plus Pem in Advanced Endometrial Cancer Phase 3
Recruiting NCT05481645 - Efficacy and Safety of TQB2450 Injection Combined With Chemotherapy ± Anlotinib Hydrochloride Capsules for Advanced Endometrial Cancer or Sarcoma of Uterus. Phase 2